{"classes":[{"title":"ACY-1215"},{"title":"Pomalidomide"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"}],"populationDescription":"All treated participants with available PK results. Prespecified to be reported for Phase 1b only. Data not collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1 day 1, Cycle 1 Day 2, Cycle 1 Day 8","title":"Plasma Levels of ACY-1215 and Pomalidomide - Phase 1b","type":"SECONDARY"}